Sandoz

Sandoz’s parent Novartis signals a renewed focus on oncology, which could influence Sandoz’s portfolio through resource allocation and partnerships in cancer therapies. Novartis’ oncology pipeline, including Pluvicto for advanced prostate cancer, is viewed as a near-term multi‑billion growth driver.

Sandoz marks one-year biosimilar launch milestone during its Summer Signature Event, highlighting team energy and a building send-off; interns lead the Replenish Middlesex County food drive to support the local community.